日本人原発性免疫不全症患者を対象としたTAK-664の延長試験

基本情報

NCT ID

NCT04842643

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

12

治験依頼者名

Takeda

概要

This study is an extension study for participants with primary immunodeficiency disorders who were previously treated with IGSC, 20% in the TAK-664-3001 study. They must have completed that study or be about to complete it before joining this study. Participants will continue treatment with IGCS, 20% in this study. The main aim of this study is to check for side effects from long-term treatment with IGSC, 20% . This medicine is not yet licensed in Japan, so participants will be treated with IGSC, 20% until it becomes commercially available.

対象疾患

介入

依頼者（Sponsor）

実施施設 (8)